Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock
January 08 2020 - 9:30PM
Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a global
biopharmaceutical company pioneering targeted C3 therapies, today
announced the pricing of its underwritten public offering of 9.5
million shares of its common stock at a public offering price of
$37.00 per share, for total gross proceeds of $351.5 million,
before deducting underwriting discounts and commissions and
expenses payable by Apellis. All of the shares in the offering are
being sold by Apellis. In addition, Apellis has granted the
underwriters a 30-day option to purchase up to 1.425 million
additional shares of its common stock at the public offering price,
less the underwriting discount and commissions. The offering is
expected to close on January 13, 2020, subject to customary closing
conditions.
Citigroup, J.P. Morgan and Evercore ISI are acting as joint
book-running managers for the offering. Cantor Fitzgerald & Co.
and Baird are acting as lead managers for the offering.
The shares are being offered by Apellis pursuant to an
automatically effective shelf registration statement that was filed
with the Securities and Exchange Commission (“SEC”) on January 7,
2020. This offering is being made only by means of a prospectus and
prospectus supplement that form a part of the registration
statement. A preliminary prospectus supplement relating to and
describing the terms of the offering has been filed with the SEC
and may be obtained for free by visiting the SEC’s website at
www.sec.gov. A final prospectus supplement relating to the offering
will be filed with the SEC. When available, copies of the final
prospectus supplement and the accompanying prospectus may also be
obtained by contacting: Citigroup Global Markets Inc., c/o
Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood,
NY 11717, telephone: 1-800-831-9146; J.P. Morgan Securities LLC,
c/o Broadridge Financial Solutions, 1155 Long Island Avenue,
Edgewood, NY 11717, telephone: (866) 803-9204; or Evercore Group
L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street,
36th Floor, New York, NY 10055, telephone: (888) 474-0200, or
email: ecm.prospectus@evercore.com.
This press release shall not constitute an offer to sell, or a
solicitation of an offer to buy these securities, nor shall there
be any sale of, these securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About Apellis Apellis Pharmaceuticals, Inc. is
a global biopharmaceutical company that is committed to leveraging
courageous science, creativity, and compassion to deliver
life-changing therapies. By pioneering targeted C3 therapies, we
aim to develop best-in-class and first-in-class therapies for a
broad range of debilitating diseases that are driven by
uncontrolled or excessive activation of the complement cascade,
including those within hematology, ophthalmology, and
nephrology.
Forward-Looking Statements
Statements in this press release about future expectations, plans
and prospects, as well as any other statements regarding matters
that are not historical facts, may constitute “forward-looking
statements” within the meaning of The Private Securities Litigation
Reform Act of 1995. These statements include, but are not limited
to, statements relating to the anticipated closing date of the
offering. The words “anticipate,” “believe,” “continue,” “could,”
“estimate,” “expect,” “intend,” “may,” “plan,” “potential,”
“predict,” “project,” “should,” “target,” “will,” “would” and
similar expressions are intended to identify forward-looking
statements, although not all forward-looking statements contain
these identifying words. Actual results may differ materially from
those indicated by such forward-looking statements as a result of
various important factors, including the uncertainties related to
market conditions and the completion of the public offering on the
anticipated terms or at all, uncertainties inherent in the
initiation of future clinical trials and other factors discussed in
the “Risk Factors” section of the preliminary prospectus supplement
filed with the SEC on January 7, 2020, Apellis’ Quarterly Report on
Form 10-Q filed with the SEC on November 5, 2019, and the risks
described in other filings that Apellis may make with the SEC. Any
forward-looking statements contained in this press release speak
only as of the date hereof, and Apellis specifically disclaims any
obligation to update any forward-looking statement, whether as a
result of new information, future events or otherwise.
Media Contact: Tracy Vineis media@apellis.com
617.420.4839
Investor Contact: Sam Martin / Maghan
Meyers Argot Partnerssam@argotpartners.com
/ maghan@argotpartners.com 212.600.1902
Apellis Pharmaceuticals (NASDAQ:APLS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Apellis Pharmaceuticals (NASDAQ:APLS)
Historical Stock Chart
From Sep 2023 to Sep 2024